rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Sutro Biopharma, Inc.

STRO · Nasdaq

Health CareBiotechnologyNot moving yet

STRO stood above a rising 150-day average in 34 of the last 52 weekly readings, and has been out of that trend for the last 10 weeks. It is 56.6% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 10
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
96 (+24)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 34 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$86KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders96+24 on the quarter
New · exited40 · 18
Reported value$533.8M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
PERCEPTIVE ADVISORS LLCadded · filed 14 Aug 20261,304,846$43.3M+589,539+82.4%
BVF INCunchanged · filed 14 Aug 20261,251,788$41.6M00.0%
Affinity Asset Advisors, LLCadded · filed 13 Aug 20261,172,487$38.9M+102,968+9.6%
BlackRock, Inc.added · filed 7 Aug 20261,122,655$37.3M+889,971+382.5%
SAMSARA BIOCAPITAL, LLCunchanged · filed 14 Aug 20261,062,872$35.3M00.0%
Kynam Capital Management, LPunchanged · filed 14 Aug 2026872,558$29.0M00.0%
ORBIMED ADVISORS LLCreduced · filed 14 Aug 2026743,944$24.7M-57,200−7.1%
Balyasny Asset Management L.P.added · filed 14 Aug 2026711,162$23.6M+245,370+52.7%
VANGUARD CAPITAL MANAGEMENT LLCreduced · filed 13 Aug 2026694,219$23.0M-26,223−3.6%
EVENTIDE ASSET MANAGEMENT, LLCreduced · filed 14 Aug 2026585,262$19.4M-130,045−18.2%
31 Mar 2023 – 30 Jun 2026
5989118Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Hans-Peter Gerber Company insiderCHIEF SCIENTIFIC OFFICER · last 18 Sep 20261 · 0
Connie Matsui Company insiderDirector · last 5 Jun 20261 · 0
Daniel H. Petree Company insiderDirector · last 5 Jun 20260 · 1
Heidi Hunter Company insiderDirector · last 5 Jun 20260 · 0
James P. Panek Company insiderDirector · last 5 Jun 20260 · 0
Jon Marc Wigginton Company insiderDirector · last 5 Jun 20260 · 0
Joseph M. Lobacki Company insiderDirector · last 5 Jun 20260 · 0
Michael Dybbs Company insiderDirector · last 5 Jun 20260 · 0
Sukhi Jagpal Company insiderDirector · last 5 Jun 20260 · 0
Gregory K. Chow Company insiderCFO · last 2 Jun 20261 · 0
David Pauling Company insiderChief Admin. Ofcr. & GC · last 4 Mar 20261 · 0
Jane Chung Company insiderChief Executive Officer · last 4 Mar 20261 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Operating profit marginFY 2025 · to 31 Dec 2025-155%
Return on capital employedFY 2025 · to 31 Dec 2025-160%
Research spendFY 2025 · to 31 Dec 2025162%
Share count trendFY 2025 · to 16 Mar 202693.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$58.1M

Analyst forecasts

No analyst forecasts yet.